Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 12, 2012, Pages 1388-1394

  Vatten, Lars J ^a   Åsvold, BjØrn O ^a,b   Eskild, Anne ^c,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

birthweight; gestational age; Hypertension in pregnancy; placental growth factor; population study; preeclampsia; soluble fms like tyrosine kinase 1

Indexed keywords

PLACENTAL GROWTH FACTOR; SOLUBLE FLT1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; NEWBORN; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; THIRD TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL MARKERS; BIRTH WEIGHT; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, SMALL FOR GESTATIONAL AGE; NORWAY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84870892084     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01516.x     Document Type: Article

References (26)

1. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al,. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992-1005.
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83.
3. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF, et al,. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol. 2005; 193: 185-91.
4. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al,. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007; 109: 1316-24.
5. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al,. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004; 89: 770-5.
6. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC,. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007; 196: 239 e1-6.
7. Åsvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A,. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol. 2011; 173: 630-9.
8. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al,. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008; 21: 279-87.
9. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al,. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008; 21: 9-23.
10. Maynard S, Epstein FH, Karumanchi SA,. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008; 59: 61-78.
11. Eskild A, Romundstad PR, Vatten LJ,. Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia? Am J Obstet Gynecol 2009; 201: 595 e1-5.
12. Vatten LJ, Skjaerven R,. Is pre-eclampsia more than one disease? Br J Obstet Gynaecol 2004; 111: 298-302.
13. Xiong X, Demianczuk NN, Buekens P, Saunders LD,. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000; 183: 148-55.
14. Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM,. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995; 173: 1097-105.
15. Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G, Whitelaw A, Eskild A, et al,. Incidence of Toxoplasma gondii infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol. 1998; 36: 2900-6.
16. Skjaerven R, Gjessing HK, Bakketeig LS,. Birthweight by gestational age in Norway. Acta Obstet Gynecol Scand 2000; 79: 440-9.
17. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, et al,. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-8.
18. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al,. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002; 160: 1405-23.
19. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al,. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
20. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al,. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-63.
21. Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, et al,. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2008; 93: 285-92.
22. Smith GC, Wear H,. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009; 21: 111-6.
23. Magnussen EB, Vatten LJ, Nilsen TIL, Salvesen KÅ, Davey Smith G, Romundstad PR,. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. Br Med J 2007; 335: 978.
24. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: preeclampsia. Am J Obstet Gynecol 2010; 202: 255.e1-7.
25. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 2009; 58: 453-9.
26. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al,. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895-903.